Anti-PD-1 Therapy-Associated Perforating Colitis
Inhibition of immune checkpoint T cell regulatory molecules by using programmed cell death protein 1 (PD-1), or its ligand (PDL-1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) has been increasingly used to treat advanced malignancies. The immune-related adverse effects associated with t...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Case Reports in Gastrointestinal Medicine |
| Online Access: | http://dx.doi.org/10.1155/2018/3406437 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849683431140622336 |
|---|---|
| author | Romulo Celli Harriet M. Kluger Xuchen Zhang |
| author_facet | Romulo Celli Harriet M. Kluger Xuchen Zhang |
| author_sort | Romulo Celli |
| collection | DOAJ |
| description | Inhibition of immune checkpoint T cell regulatory molecules by using programmed cell death protein 1 (PD-1), or its ligand (PDL-1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) has been increasingly used to treat advanced malignancies. The immune-related adverse effects associated with these treatments such as diarrhea, colitis, and CTLA-4 treatment-associated perforating colitis have been reported. However, anti-PD-1/PD-L1-associated perforating colitis has rarely been reported. We report a case of colonic perforation in a patient recently treated with pembrolizumab, a PD-1 inhibitor for metastatic melanoma. Awareness of anti-PD-1/PD-L1-associated colitis and perforation will facilitate a timely diagnosis and management as they are increasingly used in oncology. |
| format | Article |
| id | doaj-art-d81b0bc6516c4a8ba0c9dbbdbc0974f9 |
| institution | DOAJ |
| issn | 2090-6528 2090-6536 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Gastrointestinal Medicine |
| spelling | doaj-art-d81b0bc6516c4a8ba0c9dbbdbc0974f92025-08-20T03:23:52ZengWileyCase Reports in Gastrointestinal Medicine2090-65282090-65362018-01-01201810.1155/2018/34064373406437Anti-PD-1 Therapy-Associated Perforating ColitisRomulo Celli0Harriet M. Kluger1Xuchen Zhang2Department of Pathology, Section of Medical Oncology, Yale University School of Medicine, New Haven, CT, USADepartment of Medicine, Section of Medical Oncology, Yale University School of Medicine, New Haven, CT, USADepartment of Pathology, Section of Medical Oncology, Yale University School of Medicine, New Haven, CT, USAInhibition of immune checkpoint T cell regulatory molecules by using programmed cell death protein 1 (PD-1), or its ligand (PDL-1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) has been increasingly used to treat advanced malignancies. The immune-related adverse effects associated with these treatments such as diarrhea, colitis, and CTLA-4 treatment-associated perforating colitis have been reported. However, anti-PD-1/PD-L1-associated perforating colitis has rarely been reported. We report a case of colonic perforation in a patient recently treated with pembrolizumab, a PD-1 inhibitor for metastatic melanoma. Awareness of anti-PD-1/PD-L1-associated colitis and perforation will facilitate a timely diagnosis and management as they are increasingly used in oncology.http://dx.doi.org/10.1155/2018/3406437 |
| spellingShingle | Romulo Celli Harriet M. Kluger Xuchen Zhang Anti-PD-1 Therapy-Associated Perforating Colitis Case Reports in Gastrointestinal Medicine |
| title | Anti-PD-1 Therapy-Associated Perforating Colitis |
| title_full | Anti-PD-1 Therapy-Associated Perforating Colitis |
| title_fullStr | Anti-PD-1 Therapy-Associated Perforating Colitis |
| title_full_unstemmed | Anti-PD-1 Therapy-Associated Perforating Colitis |
| title_short | Anti-PD-1 Therapy-Associated Perforating Colitis |
| title_sort | anti pd 1 therapy associated perforating colitis |
| url | http://dx.doi.org/10.1155/2018/3406437 |
| work_keys_str_mv | AT romulocelli antipd1therapyassociatedperforatingcolitis AT harrietmkluger antipd1therapyassociatedperforatingcolitis AT xuchenzhang antipd1therapyassociatedperforatingcolitis |